COSCIENS Biopharma Inc. (CSCI) - רווח נקי למניה (EPS TTM)

COSCIENS Biopharma Inc. (CSCI) is optimizing the supply of rare biologics through global diversification to mitigate regulatory risks. Patents for hormonal deficiency diagnostics and FDA certification establish a sustainable market barrier. The Canadian business relies on exclusive rights and an international distribution network. Net income per share over the last four quarters demonstrates profit dynamics, with the indicator settling at -4.34.

Annual net earnings per share measures the actual business income allocated per share for an objective valuation. By analyzing changes in the rolling annual EPS, an investor can observe operational efficiency trends stripped of market noise. This calculation confirms the company's ability to generate profit from its assets. For COSCIENS Biopharma Inc. (CSCI), this indicator reflects the monetization of patents for diagnosing endocrine pathologies. The monopoly status of the drug Macrilen converts directly into the stability of this fundamental metric.